GET DAILY SIGNALSMyriad Genetics (MYGN) Advances +30% Following Prenatal Health Sale
Key Takeaways
- Myriad Genetics (MYGN) shares climbed roughly 30% over the trailing 30 days, moving from about $4.54 at the close on October 2, 2026 to approximately $5.92 in early November.
- The move was driven primarily by the announced sale of Myriad's Prenatal Health testing business to Labcorp for $210 million in cash plus inventory value at closing.
- The divestiture removes a declining segment, is expected to be accretive to revenue growth and profitability, and materially strengthens Myriad's balance sheet.
- The stock has roughly doubled over the past quarter, extending a steady recovery that began in August and accelerated after the transaction announcement.
- Analyst reactions were mixed: several firms raised price targets and one upgraded the stock, while others remained cautious on the remaining business.
- Myriad is scheduled to report third-quarter 2026 results on November 4, 2026, where management is expected to provide further commentary on the deal.
Company Background
Myriad Genetics is a Salt Lake City-based molecular diagnostics and precision medicine company that develops and commercializes genetic tests used to assess disease risk, guide treatment decisions, and support earlier detection across oncology, women's health, and mental health. Its portfolio includes hereditary cancer tests such as MyRisk and BRACAnalysis, tumor profiling products, the Prolaris prostate cancer test, and the GeneSight pharmacogenomic test. I follow the stock for its exposure to the growing precision-medicine market and its ongoing effort to reposition the business around higher-growth cancer diagnostics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance
Over the last 30 days, Myriad shares advanced from a closing price of $4.54 on October 2, 2026 to roughly $5.92 in early November, a gain of about 30%. Most of that move occurred in a single session, when the stock jumped more than 30% intraday following the Labcorp announcement. The quarterly trend is even stronger. From a close of $3.02 in early August 2026, the stock climbed steadily through September and early October before spiking in late October, reaching approximately $5.92 — a gain of roughly 96% over the period. The advance reflects both a broader recovery from depressed levels and the specific catalyst of the prenatal divestiture.
Key Catalyst Behind the Recent Move
The dominant catalyst was the October 20, 2026 announcement that Myriad had entered into a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash plus the value of related inventory at closing. The transaction includes the Prequel, Foresight, SneakPeek, and FirstGene tests, a portfolio that generated approximately $160 million in revenue over the prior twelve months and served more than 600,000 patients. Investors responded favorably because the deal addresses a segment that had been weighing on reported growth. The prenatal business recorded a double-digit year-over-year revenue decline in recent quarters, and its removal is expected to leave a more focused, faster-growing portfolio centered on cancer diagnostics. Management said the transaction is expected to be accretive to revenue growth and profitability while strengthening the balance sheet, with closing anticipated by early 2027. Analyst activity reinforced the move. Craig-Hallum raised its price target to $8 with a Buy rating, TD Cowen raised its target to $4.50 while maintaining a Hold, and Piper Sandler upgraded the stock to Neutral from Underweight with a $5 target following the announcement. Myriad also reported new MONSTAR-SCREEN-3 data highlighting the potential of its whole-genome sequencing-based Precise tests for residual disease detection in colorectal and pancreatic cancers. From what I see, this data adds another layer to the investment case.
Broader Quarterly Context
The quarterly rally reflects a gradual recovery from a low base rather than a single event. After trading near $3 in early August, the stock rose through September as investors began pricing in the possibility of a strategic divestiture of the prenatal business, a step several analysts had flagged as potentially accretive. The October 20 transaction announcement validated that thesis and triggered the sharpest gains. Supporting the broader narrative, Myriad announced in early October a collaboration with SOPHiA GENETICS to advance a prostate cancer-specific genomic instability score technology, with potential companion diagnostic applications alongside AstraZeneca. These developments reinforce management's stated focus on the cancer care continuum as its primary growth engine. I also reviewed this development using Tickeron’s AI Trend Prediction Engine for additional context on sector trends.
Upcoming Events and Outlook
Several factors are likely to shape Myriad's outlook in the months ahead. Third-quarter 2026 earnings, scheduled for November 4, 2026, will provide the first detailed commentary on the Labcorp transaction and any related organizational changes. Investors will also monitor progress toward regulatory approval and closing of the divestiture, which is expected by early 2027. Beyond the deal, key considerations include revenue growth and margin trends in the remaining cancer diagnostics and mental health businesses, reimbursement dynamics for genetic testing, competitive pressures in hereditary cancer screening, and further clinical data supporting the Precise tumor-profiling and residual-disease franchise. Analyst estimates remain spread across a wide range, reflecting differing views on whether the post-divestiture business can return to high single-digit growth. I’m watching this closely as the earnings release approaches.
Exploring AI Tools for Additional Market Context
In my analysis of names like Myriad, I often turn to Tickeron’s AI tools to cross-check signals and compare performance across peers. One resource I find particularly useful is the Trending AI Robots page, which highlights top-performing automated strategies. These can offer an extra perspective on how stocks in the diagnostics space are behaving, helping to inform a more rounded view without replacing fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MYGN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for MYGN turned positive on October 20, 2026. Looking at past instances where MYGN's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MYGN as a result. In 65 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +6.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYGN advanced for three days, in 201 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 114 of 160 cases where MYGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
MYGN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MYGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.999) is normal, around the industry mean (65.853). P/E Ratio (-5.381) is within average values for comparable stocks, (2.707). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.448) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic and predictive medicine products
Industry MedicalSpecialties
Advertisement